An innovative company, Seqirus is
commited to combatting influenza
with a portfolio of pioneering protection.
FLUAD® features the immune-enhancing
MF59® adjuvant, while FLUCELVAX®
QUADRIVALENT utilizes innovative
A Cell-Based Vaccine: Confidence Against Seasonal Influenza
At Seqirus, we've employed cell-based manufacturing, an alternative production process to traditional egg-based manufacturing, which produces a truer match to the WHO-selected strains. The use of cell-grown virus seeds eliminates egg-adapted changes to potentially improve vaccine effectiveness. Our vaccine, FLUCELVAX QUADRIVALENT, is the first and only seasonal flu vaccine developed using modern cell-based technology.2,3See Our Historical Timeline
Adjuvanted seasonal influenza vaccine
We're the proud creators of the first FDA-approved seasonal influenza vaccine that contains immune-enhancing adjuvant MF59®. MF59® is used to produce FLUAD: a seasonal influenza vaccine that helps prevent seasonal influenza in adults 65 and older.1,4
- FLUAD [package insert]. Holly Springs, NC: Seqirus Inc, 2018.
- FLUCELVAX QUADRIVALENT [package insert]. Holly Springs, NC: Seqirus Inc; 2018.
- Centers for Disease Control and Prevention. Cell-based flu vaccines. https://www.cdc.gov/flu/protect/vaccine/cell-based.htm. Updated October 4, 2018. Accessed October 24, 2018.
- Centers for Disease Control and Prevention. https://www.cdc.gov/flu/protect/vaccine/adjuvant.htm.Updated October 18, 2018. Accessed October 24, 2018.